FDA Brief

Warning letters Drugs

FDA warning letter to

Maquiladora Miniara SA de CV

High riskIssued Dec 15, 2021Posted Dec 21, 2021Center for Drug Evaluation and Research | CDER

Maquiladora Miniara's Shine and clean Hand Sanitizer Gel was found to contain methanol instead of labeled ethanol.

What happened

After an attempt to import Shine and clean Hand Sanitizer Gel labeled as manufactured at Maquiladora Miniara's facility, FDA detained and refused the shipment at the U.S. border. FDA laboratory testing of four detained batches found the product did not contain the labeled 70% ethanol; instead the batches contained methanol, with some batches averaging up to 77% methanol, along with lower or variable ethanol. FDA also held a July 9, 2020 teleconference recommending removal of the firm's hand sanitizers from the U.S. market, placed the firm's drugs on Import Alert 66-78 on July 16, 2020, and the firm recalled the product on July 24, 2020.

What FDA found

  1. The hand sanitizer was adulterated because the labeled active ingredient ethanol was replaced wholly or partly with methanol.

    FD&C Act section 501(d)(2), 21 U.S.C. 351(d)(2)
  2. The methanol substitution showed the firm's quality assurance was not working as required by current good manufacturing practice (CGMP).

    FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
  3. The product is an unapproved new drug because it is not generally recognized as safe and effective and has no FDA-approved application.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  4. The product is misbranded because it is dangerous to health when used as labeled due to methanol.

    FD&C Act section 502(j), 21 U.S.C. 352(j)
  5. The label is false or misleading because it says 70% ethanol, but testing found less ethanol and undeclared methanol.

    FD&C Act sections 502(a) and 502(e)(1)(A), 21 U.S.C. 352(a), 352(e)(1)(A)
  6. The label lacks a complete U.S. address or phone number for serious adverse event reports, and the product does not meet the OTC drug marketing rules in section 505G.

    FD&C Act sections 502(x) and 502(ee), 21 U.S.C. 352(x), 352(ee)

What FDA wants

FDA tells the firm to investigate how ethanol was substituted with methanol, list raw materials and suppliers, list all U.S.-shipped hand sanitizer batches with full batch records and distribution reconciliation, and reply in writing within 15 working days. FDA also recommends a qualified current good manufacturing practice (CGMP) consultant and a Regulatory Meeting if the firm wants to make U.S. drugs again.

Who should pay attention

  • brands or distributors that sold this hand sanitizer
  • retailers and consumers using imported hand sanitizers
  • contract manufacturers and importers of OTC drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  2. RNA Bio/Pharma, Incorporated

    FDA found RNA Bio/Pharma failed to test homeopathic oral liquid drugs for dangerous contaminants and did not validate its water system.

    High risk
  3. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  4. Ningbo Riway Industrial Co., Ltd.

    Ningbo Riway Industrial, an OTC drug maker in China, was cited for manufacturing-practice failures and unapproved antiseptic wipes.

    High risk